Introducing Injectable Contraceptives in National Family Planning Program of India: A Policy Perspective

Shuvi Sharma, Futures Group International
Manas Ranjan Pradhan, South Asia Network for Chronic Disease, PHFI

Introduction of injectable contraceptives has been controversial in India with concerns of health impact and inadequate infrastructure for follow-up and care. The study reviews the historical and legal legacy of injectables and makes recommendations for their introduction into the public sector and expanded use in the private sector. In-depth information was collected from policy makers, researchers, donor agencies, manufacturers, NGOs, and practitioners in 2010 (N=50). Provision of DMPA in the public sector is awaiting endorsement by Drug Technical Advisory Board while Cyclofem and NET-En are in the process of pre-program introduction trials for the government program. Public and private providers are most familiar with DMPA and report significant client demand. Menstrual irregularity is challenging for some clients and providers suggest counseling and follow-up. Effective strategies to expand access to injectables should provide support to the government in making DMPA available under the National Family Welfare Program.